153 related articles for article (PubMed ID: 32590748)
21. Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report.
Wu S; Liu K; Ren F; Zheng D; Pan D
BMC Pulm Med; 2018 Jul; 18(1):121. PubMed ID: 30029601
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
Davies KD; Le AT; Sheren J; Nijmeh H; Gowan K; Jones KL; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2018 Oct; 13(10):1474-1482. PubMed ID: 29935306
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
[TBL] [Abstract][Full Text] [Related]
24. Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
Dong D; Shen G; Da Y; Zhou M; Yang G; Yuan M; Chen R
Oncologist; 2020 Nov; 25(11):e1720-e1724. PubMed ID: 32652753
[TBL] [Abstract][Full Text] [Related]
25. Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
Wang Y; Chen Z; Han X; Li J; Guo H; Shi J
Oncologist; 2021 Mar; 26(3):178-181. PubMed ID: 33000474
[TBL] [Abstract][Full Text] [Related]
26. CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.
Zhu YC; Zhou YF; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G
Thorac Cancer; 2018 May; 9(5):652-655. PubMed ID: 29517860
[TBL] [Abstract][Full Text] [Related]
27. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
28. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi.
Robertson SJ; Orme L; Teixeira R; Shamassi M; Newell F; Patch AM; Yeh I; Gard G; Wilmott J; Jackett L; LeBoit P; Fellowes A; MacArthur G; Fox S; Hayward NK; Bastian B; Scolyer R; Waddell N; Penington A; Shackleton M
JAMA Dermatol; 2021 Jul; 157(7):836-841. PubMed ID: 34076666
[TBL] [Abstract][Full Text] [Related]
30. Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion.
Xie X; You M; Meng E; Wang S; Niu B; Huang W
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2561-2566. PubMed ID: 35648195
[TBL] [Abstract][Full Text] [Related]
31. Dramatic response to entrectinib in a patient with malignant peripheral nerve sheath tumor harboring novel SNRNP70-NTRK3 fusion gene.
Kobayashi H; Makise N; Shinozaki-Ushiku A; Zhang L; Ishibashi Y; Ikegami M; Tsuda Y; Kohsaka S; Ushiku T; Oda K; Miyagawa K; Aburatani H; Mano H; Tanaka S
Genes Chromosomes Cancer; 2023 Jan; 62(1):47-51. PubMed ID: 35906852
[TBL] [Abstract][Full Text] [Related]
32. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.
Diamandis P; Ferrer-Luna R; Huang RY; Folkerth RD; Ligon AH; Wen PY; Beroukhim R; Ligon KL; Ramkissoon SH
Diagn Pathol; 2016 Jan; 11():13. PubMed ID: 26817999
[TBL] [Abstract][Full Text] [Related]
33. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
[TBL] [Abstract][Full Text] [Related]
34. Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential.
Akaike K; Kurisaki-Arakawa A; Hara K; Suehara Y; Takagi T; Mitani K; Kaneko K; Yao T; Saito T
Hum Pathol; 2015 Mar; 46(3):347-56. PubMed ID: 25582503
[TBL] [Abstract][Full Text] [Related]
35. A GRIA2 and PAX8-positive renal solitary fibrous tumor with NAB2-STAT6 gene fusion.
Ichiyanagi O; Ito H; Takai S; Naito S; Kato T; Nagaoka A; Yamakawa M
Diagn Pathol; 2015 Sep; 10():155. PubMed ID: 26337721
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
[TBL] [Abstract][Full Text] [Related]
37. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
Morris TA; Khoo C; Solomon BJ
Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
[TBL] [Abstract][Full Text] [Related]
38. Primary Malignant Peripheral Nerve Sheath Tumor of the Stomach: A Rare Case Report and Review of Literature.
Cui W; Xing L; Fu L; Shi L; Li X
Int J Surg Pathol; 2023 Apr; 31(2):221-226. PubMed ID: 35491655
[TBL] [Abstract][Full Text] [Related]
39. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]